| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Pierce Kristen | Chief Development Officer | CERO THERAPEUTICS HOLDINGS, INC., 201 HASKINS WAY, SUITE 230, SOUTH SAN FRANCISCO | /s/ Andrew Kucharchuk, Attorney-in-Fact | 02 Jun 2025 | 0002039649 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CERO | Stock Option (Right to Buy) | Award | $0 | +154,841 | $0.000000 | 154,841 | 30 May 2025 | Common Stock | 154,841 | $0.4454 | Direct | F1 |
| Id | Content |
|---|---|
| F1 | The shares underlying this option shall vest in equal monthly installments through June 4, 2027. |